Related Experiment Video
Updated: Oct 15, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
miR-124-3p relieves allergic rhinitis by inhibiting dipeptidyl peptidase-4
Shitao Zhang1, Dong Dong1, Yuan Zhang1
1Department of Rhinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Abstract:
MicroRNA-124-3p (miR-124-3p) and dipeptidyl peptidase-4 (DPP4) are closely related to the development of inflammation. Allergic rhinitis (AR) models in mice and HNEpC cells were established. AR progression was assessed assessing by the frequency of nasal rubbing and sneezing, hematoxylin and eosin (HE), and TUNEL staining. Tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), eotaxin, and MUC5AC were assessed by enzyme-linked immunosorbent assay and quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Apoptosis in HNEpC cells was assessed using flow cytometry. DPP4, activated-caspase-3, and pro-caspase-3 protein expression were evaluated by western blotting. In addition, we clarified the influence of miR-124-3p-targeted DPP4 on AR inflammation and cell injury. MiR-124-3p was downregulated in AR nasal mucosa tissue. Upregulation of miR-124-3p reduced the frequency of nasal rubbing and sneezing, pathological changes, eosinophil number, and apoptosis of nasal mucosa, TNF-α and IL-6 protein and mRNA levels in serum and HNEpC cells, and MUC5AC, eotaxin, and GM-CSF levels in HNEpC cells. Downregulation of miR-124-3p has the opposite effect. Therefore, the miR-124-3p /DPP4 axis may be an attractive target for AR therapy.
Insights
MicroRNA-124-3p (miR-124-3p) is downregulated in allergic rhinitis (AR). Upregulating miR-124-3p reduces AR inflammation and cell injury by targeting dipeptidyl peptidase-4 (DPP4).
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- MicroRNA-124-3p (miR-124-3p) and dipeptidyl peptidase-4 (DPP4) play roles in inflammation.
- Allergic rhinitis (AR) is an inflammatory condition affecting the nasal mucosa.
Purpose of the Study:
- To investigate the role of the miR-124-3p/DPP4 axis in AR.
- To explore miR-124-3p as a potential therapeutic target for AR.
Main Methods:
- Established mouse and human nasal epithelial cell (HNEpC) models of AR.
- Assessed AR progression via clinical symptoms, histology (HE, TUNEL), and inflammatory markers (TNF-α, IL-6, GM-CSF, eotaxin, MUC5AC) using ELISA and qRT-PCR.
- Evaluated apoptosis via flow cytometry and protein expression (DPP4, caspase-3) via western blotting.
Main Results:
- miR-124-3p was downregulated in AR nasal mucosa.
- Upregulating miR-124-3p alleviated AR symptoms, reduced inflammation, eosinophil infiltration, and apoptosis in nasal mucosa.
- miR-124-3p targeted DPP4, influencing AR inflammation and cell injury.
Conclusions:
- The miR-124-3p/DPP4 axis is implicated in AR pathogenesis.
- Modulating miR-124-3p offers a potential therapeutic strategy for allergic rhinitis.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

